$5.23
0.19% yesterday
Nasdaq, Dec 20, 10:05 pm CET
ISIN
US03589W1027
Symbol
ANNX
Sector
Industry

Annexon Inc Stock price

$5.23
+0.07 1.36% 1M
+0.03 0.58% 6M
+0.69 15.20% YTD
+2.35 81.60% 1Y
-8.02 60.53% 3Y
-12.53 70.55% 5Y
-12.53 70.55% 10Y
Nasdaq, Closing price Fri, Dec 20 2024
+0.01 0.19%
ISIN
US03589W1027
Symbol
ANNX
Sector
Industry

Key metrics

Market capitalization $557.49m
Enterprise Value $246.98m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.67
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-131.60m
Free Cash Flow (TTM) Free Cash Flow $-105.48m
Cash position $340.12m
EPS (TTM) EPS $-1.04
P/E forward negative
Short interest 8.80%
Show more

Is Annexon Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.

Annexon Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Annexon Inc forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Annexon Inc forecast:

Buy
100%

Financial data from Annexon Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 3.41 3.41
1% 1%
-
-3.41 -3.41
1% 1%
-
- Selling and Administrative Expenses 25 25
4% 4%
-
- Research and Development Expense 99 99
17% 17%
-
-128 -128
13% 13%
-
- Depreciation and Amortization 3.41 3.41
1% 1%
-
EBIT (Operating Income) EBIT -132 -132
13% 13%
-
Net Profit -118 -118
17% 17%
-

In millions USD.

Don't miss a Thing! We will send you all news about Annexon Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Annexon Inc Stock News

Neutral
GlobeNewsWire
5 days ago
BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to nine new non-executive employees under the terms of the ...
Neutral
GlobeNewsWire
5 days ago
Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study (IGOS) Matched Cohort Study Showed Early and Greater Benefits of ANX005 over IVIg or PE in Muscle Strength and Functional Outcomes Across Multiple Measurements Conference Call and We...
Neutral
GlobeNewsWire
about one month ago
BRISBANE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to seven new non-executive employees under the terms of the...
More Annexon Inc News

Company Profile

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in South San Francisco, CA.

Head office United States
CEO Douglas Love
Employees 71
Founded 2011
Website www.annexonbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today